Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Aquestive Therapeutics, Inc. reported revenue of $45M, down 22.6% year over year. Operating margin was -159.5% and net margin -188.1%, on a free-cash-flow margin of -119.0% with capital expenditure at 1.3% of revenue. Every figure is computed directly from AQST's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $45M | -159.5% | -188.1% |
| FY2024 | $58M | -53.5% | -76.7% |
| FY2023 | $51M | -29.9% | -15.6% |
| FY2022 | $48M | -88.2% | -114.1% |
| FY2021 | $51M | -68.2% | -138.8% |
How does AQST compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.